The primary endpoint ( PEP ) and its component , hospitalisation for worsening HF , were more frequent in COPD patients ( HRs f , @ -LSB- p = @ -RSB- ; and @ -LSB- p < @ -RSB- ) respectively , but relative risk was reduced similarly by ivabradine in both COPD ( @ % , and @ % ) and non-COPD ( @ % and @ % ) patients ( p interaction = @ , and @ , respectively ) .